Zoetis Inc.

Date: May 13, 2024.

Company’s Overview

Zoetis Inc. (ZTS) reigns supreme as the world’s largest animal health company. Spanning over 100 countries, they develop, manufacture, and market medicines, vaccines, diagnostics, and technologies to keep pets and livestock healthy and productive. From treating common pet ailments to preventing livestock diseases, Zoetis offers a comprehensive suite of animal health solutions.

Competition

Revenue Segments

The Company’s net sales proportions by segment for the most recent quarterly report are composed by:

Related Risks

Even Zoetis, the animal health leader, faces hurdles. Evolving regulations and government pricing pressures can limit their ability to launch new products or maintain existing margins. Supply chain disruptions can hinder production or materials sourcing. Increased competition from generics and other animal health companies can threaten their market share and profitability. The growing threat of antibiotic resistance in animals might lead to tighter regulations and lower demand for certain medications. Additionally, an economic downturn could reduce spending on animal healthcare by pet owners and livestock producers. To stay ahead, Zoetis needs to focus on innovation, navigating regulations effectively, managing costs tightly, ensuring a reliable supply chain, and addressing antimicrobial resistance concerns.

Financial Performance

Company’s Revenues

Revenues from 2021 to 2023:

• Zoetis annual revenue for 2023 was $8.544B, a 5.74% increase from 2022.
• Zoetis annual revenue for 2022 was $8.08B, a 3.91% increase from 2021.
• Zoetis annual revenue for 2021 was $7.776B, a 16.49% increase from 2020.

The yearly revenue from 2010 till 2023 is:

**The 2024 and 2025 values are the expected by the analysts

Company’s Net Income

Net Income from 2021 to 2023:

• Zoetis annual net income for 2023 was $2.344B, a 10.88% increase from 2022.
• Zoetis annual net income for 2022 was $2.114B, a 3.78% increase from 2021.
• Zoetis annual net income for 2021 was $2.037B, a 24.36% increase from 2020.

The yearly net income from 2010 till 2023 is:

**The 2024 and 2025 values are the expected by the analysts

Company’s EPS

EPS from 2021 to 2023:

• Zoetis 2023 annual EPS was $5.07, a 12.92% increase from 2022.
• Zoetis 2022 annual EPS was $4.49, a 5.15% increase from 2021.
• Zoetis 2021 annual EPS was $4.27, a 24.85% increase from 2020.

Company’s Free Cash Flow

Free Cash Flow from 2021 to 2023:

• Zoetis annual free cash flow for 2023 was $1.625B, a 22.46% increase from 2022.
• Zoetis annual free cash flow for 2022 was $1.327B, a 23.65% decline from 2021.
• Zoetis annual free cash flow for 2021 was $1.738B, a 2.6% increase from 2020.

The yearly free cash flow from 2010 till 2023 is:

**The 2024 and 2025 values are the expected by the analysts

Shares Outstanding

In December 2021, our Board of Directors authorised a $3.5 billion share repurchase program. As of December 31, 2023, there was $1.5 billion remaining under this

authorisation.

The Company overall has increased its shares outstanding by almost 8.5% from 2010.

Financial Strength

Their Asset-to-liability ratio of 1.54 indicates that for every $1 they owe in liabilities, they have $1.54 in assets to cover them. This ratio is below the ideal level of 2, suggesting a tighter financial situation and less room for unexpected costs or strategic investments.

The current ratio which is 3.36 measures a company’s ability to meet its short-term obligations (due within a year) using short-term assets (cash, receivables). A ratio above 1 is generally considered acceptable, and 3.36 indicates Zoetis has ample resources to cover their short-term debts comfortably.

The Company’s net debt of $4.8 billion is a concern. While Zoetis did manage to reduce their net debt in 2020 and 2021, the increase back to 2019 levels in 2022 and 2023 raises some questions. This higher debt level could limit their financial flexibility and impact their ability to invest in research and development or make strategic acquisitions.

Valuation

Based on the analysis performed, ZTS’s price is slightly overvalued. As key metrics, we considered 10% Required Rate of Return (RRR) and 20% margin of safety. Note that in the analysis we take into consideration also the cash and cash equivalents and the total debt.

The company has received a range of ratings from buy to sell. Specifically, there were 14 buy, 3 overweight, 1 hold, 1 underweight and 0 sell ratings. The consensus rating leans toward overweight.

Zoetis stands out as a compelling player in the animal health industry. Their financial performance is impressive, boasting a double-digit 10-year CAGR for revenue (5.97%), net income (14.93%), and free cash flow (13.55%). This consistent growth is further amplified by a significant decrease in outstanding shares (almost 9% since 2011), resulting in a stellar 10-year EPS CAGR of 15.92%. Their profitability reigns supreme with gross and net margins exceeding industry averages by a significant margin (70.06% vs 46.83% and 27.43% vs 3.76%, respectively). Additionally, their return on invested capital (ROIC) of 23.25% demonstrates exceptional efficiency in utilising resources.

However, some concerns linger. Competition in the animal health industry can pose a threat, and the stock price appears slightly overvalued with a P/E ratio of 28.84 compared to the industry median of 22.79. Their net debt of $4.8 billion is a notable point, though it was successfully reduced in 2020 and 2021 before rising back to 2019 levels in recent years. While the liquidity ratio of 3.36 indicates adequate resources to cover short-term obligations, the asset-to-liability ratio of 1.54 suggests a tighter financial situation.

Overall, Zoetis offers a unique combination of impressive profitability, strong growth, and efficient resource allocation. While competition and valuation are factors to consider, their financial strength is improving, and their commitment to innovation positions them well for continued success in the animal health market. Investors seeking a company with a strong track record and compelling growth prospects should seriously consider Zoetis, but careful due diligence is always recommended before making any investment decisions.

Affiliate

Trade with confidence on Freedom24, your trustworthy and licensed EU broker. Sign up using my referral link (https://freedom24.com/invite_from/2161547) and get a free stock worth up to $700! (Offer for engaged EU residents over 25).

Blog

https://alphacapital99.wordpress.com

Disclaimer

Please note that I am not a licensed financial advisor and the information provided here should not be construed as financial advice. I am simply sharing my understanding of the topics based on my research and personal experiences. It is always advisable to consult with a qualified financial advisor before making any investment decisions.

The information I provide is based on publicly available sources and my own interpretations. I strive to provide accurate and up-to-date information, but I cannot guarantee the correctness or completeness of the information.

Any opinions expressed here are my own and do not necessarily reflect the views of any other individual or organisation.

Please use your own judgement and conduct your own research before making any investment decisions.